Watchlist

Watchlist
AmpliPhi Biosciences Corporation (APHB)
AmpliPhi Biosciences Corporation (APHB)
Reader Inquiry: Is A Run-Up In The Cards For AmpliPhi BioSciences?
Shares of AmpliPhi Biosciences (APHB) have lost nearly three quarters of their value since the beginning of 2017, with investors sucked in by the exciting story of their bacteriophage therapies taking quite the beating. Year to date, the stock has risen by 15% (at one point over 50% in March)….
AmpliPhi Biosciences to Present at 5th World Congress on Targeting Infectious Diseases: Targeting Phage & Antibiotic Resistance 2018
AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced its participation in the 5 th World Congress on Targeting Infectious Diseases &#x201…
Ampliphi Biosciences Corp. 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Ampliphi Biosciences Corp. in conjunction with their 2018 Q1 earnings Read more …
AmpliPhi Biosciences' (APHB) CEO Paul Grint on Q1 2018 Results - Earnings Call Transcript
AmpliPhi Biosciences Corporation (APHB) Q1 2018 Results Earnings Conference Call May 15, 2018 04:30 PM ET Executives Matt Dansey - Manager, Business Development Paul Grint - CEO Igor Bilinsky - COO Steve Martin - CFO Analysts Joe Pantginis - HC Wainwright David Bautz - …
AmpliPhi Biosciences misses by $0.05
AmpliPhi Biosciences (NYSEMKT: APHB ): Q1 EPS of -$0.24 misses by $0.05 . More news on: Ampliphi Biosciences Corp., Earnings news and commentary, Healthcare stocks news, , Read more …
AmpliPhi Biosciences Reports First Quarter 2018 Financial Results and Business Highlights
Announced positive topline results for the initial seven patients treated with AB-SA01 or AB-PA01 under ongoing expanded access program and presented detailed results for the first patient at a medical conference Signed collaborative agreements with the U.S. Department of Veterans A…
AmpliPhi Biosciences to Hold 2018 First Quarter and Business Update Conference Call on May 15
AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that management will hold a business update conference call on Tuesday,…
AmpliPhi Biosciences Will Utilize NIAID Preclinical Services to Advance Development of Its Targeted Therapeutic Candidate for the Treatment of Resistant Staphylococcus Aureus
AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it will utilize the Therapeutic Development Services funded by the National Inst…
Key events next week - healthcare
Noteworthy events during the week of April 8 - 14 for healthcare investors. More news on: Avita Medical Ltd., Immunovaccine Inc., Intercept Pharmaceuticals, Healthcare stocks news, , Read more …
AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Study at ISHLT Annual Meeting
AmpliPhi Biosciences Corporation (NYSE American: APHB) , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the presentation of a case study of a lung transplant recipient suffering from a resi…
AmpliPhi Biosciences Corporation (APHB)
AmpliPhi Biosciences Corporation (APHB)